Yiğit Yilmaz, Mesut Melih Özercan, Burcu Ancin, Zeliha Günnur Dikmen, Meltem Cağlar Tuncali, Murat Tuncel, Serkan Uysal, Ulaş Kumbasar, Erkan Dikmen, Rıza Doğan
{"title":"HE4水平与非小细胞肺癌患者PET代谢参数的关系","authors":"Yiğit Yilmaz, Mesut Melih Özercan, Burcu Ancin, Zeliha Günnur Dikmen, Meltem Cağlar Tuncali, Murat Tuncel, Serkan Uysal, Ulaş Kumbasar, Erkan Dikmen, Rıza Doğan","doi":"10.1080/17520363.2025.2471744","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To investigate the relationship between serum human epididymis protein 4 (HE4) levels and metabolic parameters of positron emission tomography (PET) imaging in patients with lung cancer.</p><p><strong>Methods: </strong>Sixty non-small cell lung cancer (NSCLC) patients were included in this prospective study. Demographic information, smoking status, comorbid pathologies, preoperative HE4 levels, PET imaging metabolic parameters, disease stage and histopathology were recorded.</p><p><strong>Results: </strong>Significant positive correlations between serum HE4 levels and all the metabolic parameters were observed (<i>p</i> < 0.05). In univariate regression analyses, it was observed that high serum HE4 levels could indicate tumor be squamous cell carcinoma (SCC) (<i>p</i> = 0.029), advanced T stage (<i>p</i> = 0.041), and have high maximum standart uptake value (SUVmax) (<i>p</i> = 0.017).</p><p><strong>Conclusion: </strong>Serum HE4 levels can be used as a biomarker to predict tumor burden and metabolic activity for NSCLC patients. Although sufficient per power analysis, this study may have benefited from further expansion, and by patient heterogeneity in TNM stage and tumor histology, potentially affecting the assessment of parameter relationships.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"259-265"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970736/pdf/","citationCount":"0","resultStr":"{\"title\":\"Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patients.\",\"authors\":\"Yiğit Yilmaz, Mesut Melih Özercan, Burcu Ancin, Zeliha Günnur Dikmen, Meltem Cağlar Tuncali, Murat Tuncel, Serkan Uysal, Ulaş Kumbasar, Erkan Dikmen, Rıza Doğan\",\"doi\":\"10.1080/17520363.2025.2471744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To investigate the relationship between serum human epididymis protein 4 (HE4) levels and metabolic parameters of positron emission tomography (PET) imaging in patients with lung cancer.</p><p><strong>Methods: </strong>Sixty non-small cell lung cancer (NSCLC) patients were included in this prospective study. Demographic information, smoking status, comorbid pathologies, preoperative HE4 levels, PET imaging metabolic parameters, disease stage and histopathology were recorded.</p><p><strong>Results: </strong>Significant positive correlations between serum HE4 levels and all the metabolic parameters were observed (<i>p</i> < 0.05). In univariate regression analyses, it was observed that high serum HE4 levels could indicate tumor be squamous cell carcinoma (SCC) (<i>p</i> = 0.029), advanced T stage (<i>p</i> = 0.041), and have high maximum standart uptake value (SUVmax) (<i>p</i> = 0.017).</p><p><strong>Conclusion: </strong>Serum HE4 levels can be used as a biomarker to predict tumor burden and metabolic activity for NSCLC patients. Although sufficient per power analysis, this study may have benefited from further expansion, and by patient heterogeneity in TNM stage and tumor histology, potentially affecting the assessment of parameter relationships.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"259-265\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970736/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2471744\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2471744","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patients.
Aim: To investigate the relationship between serum human epididymis protein 4 (HE4) levels and metabolic parameters of positron emission tomography (PET) imaging in patients with lung cancer.
Methods: Sixty non-small cell lung cancer (NSCLC) patients were included in this prospective study. Demographic information, smoking status, comorbid pathologies, preoperative HE4 levels, PET imaging metabolic parameters, disease stage and histopathology were recorded.
Results: Significant positive correlations between serum HE4 levels and all the metabolic parameters were observed (p < 0.05). In univariate regression analyses, it was observed that high serum HE4 levels could indicate tumor be squamous cell carcinoma (SCC) (p = 0.029), advanced T stage (p = 0.041), and have high maximum standart uptake value (SUVmax) (p = 0.017).
Conclusion: Serum HE4 levels can be used as a biomarker to predict tumor burden and metabolic activity for NSCLC patients. Although sufficient per power analysis, this study may have benefited from further expansion, and by patient heterogeneity in TNM stage and tumor histology, potentially affecting the assessment of parameter relationships.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
